Novel Tumor-Specific Antigens for Immunotherapy Identified From Multi-omics Profiling in Thymic Carcinomas
Open Access
- 16 November 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Abstract
Thymic carcinoma (TC) is the most aggressive thymic epithelial neoplasm. TC patients with microsatellite instability, whole-genome doubling, or alternative tumor-specific antigens from gene fusion are most likely to benefit from immunotherapies. However, due to the rarity of this disease, how to prioritize the putative biomarkers and what constitutes an optimal treatment regimen remains largely unknown. Therefore, we integrated genomic and transcriptomic analyses from TC patients and revealed that frameshift indels in KMT2C and CYLD frequently produce neoantigens. Moreover, a median of 3 fusion-derived neoantigens was predicted across affected patients, especially the CATSPERB-TC2N neoantigens that were recurrently predicted in TC patients. Lastly, potentially actionable alterations with early levels of evidence were uncovered and could be used for designing clinical trials. In summary, this study shed light on our understanding of tumorigenesis and presented new avenues for molecular characterization and immunotherapy in TC.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 109-2320-B-002-016-MY3)
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Nos.82073285, Nos.82072569)
- Shanghai Jiao Tong University (No.ZH2018ZDA27)
- Shanghai Chest Hospital (YJXT20190104, 2018YNJCM06)
This publication has 58 references indexed in Scilit:
- Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome EvolutionCancer Discovery, 2014
- Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2Current Protocols in Human Genetics, 2013
- MuSiC: Identifying mutational significance in cancer genomesGenome Research, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Thymic Malignancies: From Clinical Management to Targeted TherapiesJournal of Clinical Oncology, 2011
- Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutationsLaboratory Investigation, 2009
- Exdpf Is a Key Regulator of Exocrine Pancreas Development Controlled by Retinoic Acid and ptf1a in ZebrafishPLOS Biology, 2008
- SIFT: predicting amino acid changes that affect protein functionNucleic Acids Research, 2003
- Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigensInternational Journal of Cancer, 2001
- Recurrent Genetic Aberrations in Thymoma and Thymic CarcinomaThe American Journal of Pathology, 2000